AstraZeneca scored a win on Friday as data showed its antibody cocktail is 77 percent effective at preventing symptomatic COVID-19 in high-risk populations.
The research found no one who took AstraZeneca’s combination, called AZD7442, developed severe COVID-19 or died due to the virus. In comparison, three participants who received the placebo endured serious illness, with two fatalities.
AstraZencea called the treatment, involving the antibodies ixagevimab and cilgavimab, the first “long-acting antibody combination to prevent COVID-19” in a release.
Overall, 25 positive coronavirus infections were confirmed in the Provent study involving more than 5,100 patients across sites in the U.S., U.K., Belgium, France and Spain. The participants were unvaccinated at the time and had a negative test.